The European Commission has fined Teva €462.6 million for abusing its dominant position to delay competition to its blockbuster medicine for the treatment of multiple sclerosis, Copaxone. The...
The pandemic has triggered a greater interest among patients about Europe’s role in medicine manufacturing. New research reveals that seven in 10 patients now want to know...
The European Commission has fined the pharmaceutical companies Teva (€30 million) and Cephalon (€30.5 million) a total of €60.5 million for a ‘pay for delay’ agreement...
The European Commission has sent a supplementary Statement of Objections to Teva Pharmaceutical Industries Ltd. (“Teva”) and Cephalon Inc. (“Cephalon”), now a subsidiary of Teva. This...
